O Fernandez-Fernandez

Summary

Affiliation: Instituto de la Grasa
Country: Spain

Publications

  1. ncbi [Genetic and environmental factors in multiple sclerosis]
    O Fernandez
    Servicio de Neurologia, Complejo Hospitalario Universitario Carlos Haya, Malaga, Espana
    Rev Neurol 30:964-7. 2000
  2. ncbi Clinical benefits of interferon beta-1a in relapsing-remitting MS: a phase IV study
    O Fernandez
    Department of Neurology, Hospital Regional Universitario Carlos Haya, Malaga, Spain
    Acta Neurol Scand 107:7-11. 2003
  3. ncbi [Clinical features of relapsing remitting-multiple sclerosis. Prognostic factors]
    O Fernandez-Fernandez
    Servicio de Neurología Hospital Regional Universitario Carlos Haya, Malaga, Espana
    Rev Neurol 35:1067-73. 2002
  4. ncbi Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study
    Oscar Fernandez
    Servicio de Neurologia, Complejo Hospitalario Carlos Haya Avda, Carlos Haya, 29010 Malaga, Spain
    J Neurol 249:1058-62. 2002
  5. ncbi Mechanisms and current treatments of urogenital dysfunction in multiple sclerosis
    Oscar Fernandez
    Neurological Service, Complejo Hospitalario Carlos Haya, Malaga, Spain
    J Neurol 249:1-8. 2002
  6. ncbi Study of binding and neutralising antibodies to interferon-beta in two groups of relapsing-remitting multiple sclerosis patients
    O Fernandez
    Neurology Service, Carlos Haya Hospital, Malaga, Spain
    J Neurol 248:383-8. 2001
  7. ncbi [The rational basis of the newer treatments used in multiple sclerosis]
    O Fernandez
    Servicio de Neurologia, Complejo Hospitalario Universitario Carlos Haya, Malaga, Espana
    Rev Neurol 30:1257-64. 2000
  8. ncbi [Interferon-beta response in multiple sclerosis associated with pre-treatment disability]
    O Fernandez-Fernandez
    Instituto de Neurociencias clínicas, Hospital Regional Universitario Carlos Haya, Malaga, Espana
    Rev Neurol 43:322-9. 2006
  9. ncbi HLA class II and response to interferon-beta in multiple sclerosis
    O Fernandez
    Institute of Clinical Neurosciences, Hospital Regional Universitario Carlos Haya, Malaga, Spain
    Acta Neurol Scand 112:391-4. 2005
  10. doi Multiple sclerosis in Gypsies from southern Spain: prevalence, mitochondrial DNA haplogroups and HLA class II association
    O Fernandez
    Institute of Clinical Neurosciences, Hospital Regional Universitario Carlos Haya, Malaga, Spain
    Tissue Antigens 71:426-33. 2008

Detail Information

Publications13

  1. ncbi [Genetic and environmental factors in multiple sclerosis]
    O Fernandez
    Servicio de Neurologia, Complejo Hospitalario Universitario Carlos Haya, Malaga, Espana
    Rev Neurol 30:964-7. 2000
    ..Multiple sclerosis is expressed in genetically susceptible persons randomly affected by an unknown environmental factor, probably a virus, which sets off an abnormal immune process...
  2. ncbi Clinical benefits of interferon beta-1a in relapsing-remitting MS: a phase IV study
    O Fernandez
    Department of Neurology, Hospital Regional Universitario Carlos Haya, Malaga, Spain
    Acta Neurol Scand 107:7-11. 2003
    ..To evaluate the efficacy and safety of IFNbeta-1a (Avonex, Biogen, Inc., Cambridge, MA, USA) in patients with relapsing-remitting multiple sclerosis (MS)...
  3. ncbi [Clinical features of relapsing remitting-multiple sclerosis. Prognostic factors]
    O Fernandez-Fernandez
    Servicio de Neurología Hospital Regional Universitario Carlos Haya, Malaga, Espana
    Rev Neurol 35:1067-73. 2002
    ....
  4. ncbi Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study
    Oscar Fernandez
    Servicio de Neurologia, Complejo Hospitalario Carlos Haya Avda, Carlos Haya, 29010 Malaga, Spain
    J Neurol 249:1058-62. 2002
    ..In conclusion, combination therapy with IFNB-1b and AZA was safe and generally well tolerated in patients with SPMS. Strict clinical and laboratory monitoring is recommended during this combination therapy...
  5. ncbi Mechanisms and current treatments of urogenital dysfunction in multiple sclerosis
    Oscar Fernandez
    Neurological Service, Complejo Hospitalario Carlos Haya, Malaga, Spain
    J Neurol 249:1-8. 2002
    ..As most urogenital symptoms of MS can now be treated by conservative means, expert urological or gynaecological consultation should be requested only if more aggressive diagnostic or therapeutic measures are needed...
  6. ncbi Study of binding and neutralising antibodies to interferon-beta in two groups of relapsing-remitting multiple sclerosis patients
    O Fernandez
    Neurology Service, Carlos Haya Hospital, Malaga, Spain
    J Neurol 248:383-8. 2001
    ..This may be due to the non-glycosylated, chemical structure of the former, which can produce aggregates and enhance antibody production. No association was found between the presence of NABs and the clinical status of the patients...
  7. ncbi [The rational basis of the newer treatments used in multiple sclerosis]
    O Fernandez
    Servicio de Neurologia, Complejo Hospitalario Universitario Carlos Haya, Malaga, Espana
    Rev Neurol 30:1257-64. 2000
    ..Multiple sclerosis is a disease known as a clinicopathological entity since more than a century, but its ethiology remains unknown till today...
  8. ncbi [Interferon-beta response in multiple sclerosis associated with pre-treatment disability]
    O Fernandez-Fernandez
    Instituto de Neurociencias clínicas, Hospital Regional Universitario Carlos Haya, Malaga, Espana
    Rev Neurol 43:322-9. 2006
    ..To study pre-treatment clinical features and influence of neutralising antibodies (NABs) in clinical response to interferon-beta (IFNB)...
  9. ncbi HLA class II and response to interferon-beta in multiple sclerosis
    O Fernandez
    Institute of Clinical Neurosciences, Hospital Regional Universitario Carlos Haya, Malaga, Spain
    Acta Neurol Scand 112:391-4. 2005
    ..To study the relationship between human leucocyte antigen (HLA) genotype and clinical response to interferon-beta (IFN-beta)...
  10. doi Multiple sclerosis in Gypsies from southern Spain: prevalence, mitochondrial DNA haplogroups and HLA class II association
    O Fernandez
    Institute of Clinical Neurosciences, Hospital Regional Universitario Carlos Haya, Malaga, Spain
    Tissue Antigens 71:426-33. 2008
    ..DQB1*0602 was the strongest positive association found with Gypsy MS patients, and DRB1*1501-DQB1*0602 was the most frequent haplotype in this group...
  11. ncbi [Tolosa-Hunt syndrome and orbital pseudotumour. Overlapping conditions in a case with an unusual clinical profile]
    O Hamad-Cueto
    Department of Neurology, Hospital Regional Universitario Carlos Haya, Avda Carlos Haya s n, E 29010 Malaga, Spain
    Rev Neurol 42:530-4. 2006
    ..Yet, the association of both processes in the same patient, with radiological proof of the migration of the inflammatory injury, is not frequent...
  12. ncbi Azathioprine and methotrexate in multiple sclerosis
    O Fernandez
    Instituto de Neurociencias, Servicio de Neurologia, Hospital Regional Universitario Carlos Haya, Malaga, Spain
    J Neurol Sci 223:29-34. 2004
    ..Methotrexate may alter the course of disease favourably in patients with progressive MS, but the evidence is again sparse...
  13. ncbi DQB1*0602 allele shows a strong association with multiple sclerosis in patients in Malaga, Spain
    O Fernandez
    Dept of Neurology, Hospital Regional Universitario Carlos Haya, Avda Carlos Haya s n, 29010 Malaga, Spain
    J Neurol 251:440-4. 2004
    ..The human leukocyte antigen (HLA) class II DR2 haplotype (DRB1*1501, DQA1*0102, DQB1*0602) has been associated with multiple sclerosis (MS) in all ethnic groups and very strongly in Caucasians...